Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 20 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

85%

17 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
9(50.0%)
Phase 3
8(44.4%)
Phase 1
1(5.6%)
18Total
Phase 4(9)
Phase 3(8)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT07475000Phase 3Recruiting

Second Dose of Varicella Vaccine in Healthy Children

Role: lead

NCT07473427Phase 3Not Yet Recruiting

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial

Role: lead

NCT06994052Phase 4Completed

Study on Booster Immunization With Varicella Vaccine at Different Intervals

Role: lead

NCT06987942Phase 4Completed

Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)

Role: lead

NCT06891872Phase 4Not Yet Recruiting

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

Role: lead

NCT06482216Not Yet Recruiting

Correlation of Protection Against Varicella in an Exploratory Study

Role: lead

NCT06314724Phase 3Completed

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

Role: lead

NCT06484686Phase 4Enrolling By Invitation

An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine

Role: lead

NCT05095701Phase 4Enrolling By Invitation

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

Role: lead

NCT05015686Phase 3Enrolling By Invitation

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

Role: lead

NCT05470855Phase 4Unknown

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

Role: lead

NCT05460429Phase 4Unknown

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

Role: lead

NCT05526820Phase 4Completed

A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine

Role: lead

NCT05150392Phase 3Completed

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

Role: lead

NCT05145166Completed

Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old

Role: lead

NCT04364399Phase 4Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

Role: lead

NCT03555071Phase 3Completed

A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine

Role: lead

NCT02981836Phase 3Completed

A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines

Role: lead

NCT02692599Phase 3Completed

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Role: lead

NCT02965404Phase 1Completed

A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children

Role: lead

All 20 trials loaded